ClinicalTrials.gg
CompletedNCT00641953Updated Jun 17, 2008

IMX-150 Cream for Diabetic Neuropathy

A Phase 2 interventional study of IMX-150 and IMX-150 in Diabetic Peripheral Neuropathy, sponsored by Procris Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-06-17.

Sponsored by Procris Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare the effectiveness of two different dose of IMX-150 to that of placebo (non-active) in the treatment of diabetic peripheral neuropathy pain of the feet.

02

Conditions studied

  • Diabetic Peripheral Neuropathy

Keywords

  • Foot Pain
  • Diabetic Neuropathy Pain
  • Diabetic Peripheral Neuropathy foot pain
03

In context

Lead sponsor

Procris Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have sufficient command and understanding of the English language to complete diaries and questionnaires
  • If female, may not be pregnant or lactating
  • Can be treated on an outpatient basis
  • Has a clinical diagnosis of Type-1 or Type II diabetes with: confirmed diagnosis of diabetic distal symmetrical sensorimotor polyneuropathy and bilateral pain in the feet for at least 3 months.
  • Must have a value of 11% or less that is stable under treatment
  • Agrees to use the test creams as specified for the 4 week period
  • Willing to not use any other medications, including medications, to treat pain symptoms of Diabetic Neuropathy while in study.

Exclusion criteria

Exclusion Criteria:

  • Currently using any nitrate medications
  • Currently using Viagra®, Levitra®, Cialis® or other phosphodiesterase 5 inhibitors medications for erectile dysfunction
  • Currently treated for symptoms of diabetic neuropathy, including but not limited to Lyrica®, Cymbalta® and transcutaneous stimulation
  • Not on a stable dose for at least 4 weeks prior to study screening of other vasodilators required for underlying conditions
  • Know allergy to Nitroglycerin, propylene glycol or common moisturizing creams
  • History of migraine, cluster or vascular headaches, chronic pain with greater pain intensity than the pain of diabetic neuropathy or other chronic pain condition within the region of the diabetic peripheral neuropathy
  • Amputation of more than one toe per foot
  • Neurological disorder or skin condition that may alter local sensation in the feet
  • History of unstable medical problem, screening laboratory test or any current medical condition that would contraindicate the administration of the study mediation, interfere with the study evaluations, or interfere with the patient's ability to comply with the study
  • History of drug (including cannabinoid) or alcohol abuse within the past year
  • Cognitive or language difficulties that would impair completion of the pain assessment tool
  • Within the past 3 months, have had either a myocardial infarction, uncontrolled hypotension, or uncontrolled hypertension
  • Participated in a study of any drug within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to Screening
  • Major abdominal, thoracic or vascular surgery within 6 months of the first dose of study medication
  • Open lesions in the area where the cream is to be applied
  • Fertile patients who are unable or unwilling to comply with the requirements during the study period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    A

    IMX-150 (0.3%) 0.5 g topically BID each foot

    Drug: IMX-150

  • Experimental
    B

    IMX-150(0.6%) 0.5 g topically BID to each foot

    Drug: IMX-150

  • Placebo comparator
    C

    Placebo 0.5 g topically BID to each foot for 4 weeks

    Drug: Placebo

Interventions

  • (0.3%) 0.5g topically BID to each foot for 4 weeks

  • (0.6%) 0.5g topically BID to each foot for 4 weeks

  • DrugPlacebo

    0.5 g topically BID to each foot for 4 weeks

06

What researchers measure

Primary outcomes

  1. Change from Baseline to endpoint (Day 29) in the average of neuropathic foot daily pain "24 - Hour Average Pain" scores

    Time frame: Weekly average of "24-hour Average Pain"

Secondary outcomes

  1. Change in weekly average sleep disturbance

    Time frame: daily

07

Study locations

7 sites
  • Meriden Research
    Brooksville, Florida 34613, United States
  • Health Awareness
    Jupiter, Florida 33458, United States
  • International Research Associates, LLC
    Miami, Florida 33156, United States
  • Peninsula Research
    Ormond Beach, Florida 32174, United States
  • Alpha Medical Research
    Oviedo, Florida 32765, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Hampton Roads Center for Clinical Research
    Norfolk, Virginia 23502, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2008
First posted
Mar 24, 2008
Start
Aug 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Jun 17, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00641953
Lead sponsor
Procris Pharmaceuticals
First posted
Mar 24, 2008
Start date
Aug 2007
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Jun 17, 2008

Study contacts

Patrick Yeramian, MD
study director · VP Medical Affairs

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion